

CARDIFF AND VALE UNIVERSITY HEALTH BOARD
CORPORATE MEDICINES MANAGEMENT GROUP
NOTES OF MEETING HELD ON THURSDAY 1st SEPTEMBER 2022

Present: Clinical Director Pharmacy and Medicines Management (Chair), Specialist Pharmacist Mental Health (item 7b), Clinical Board Pharmacist Specialist Services, Lead Medicines Access Pharmacist, Clinical Board Pharmacist PCIC, Clinical Board Pharmacist Surgery, LMC rep1, Clinical Board Pharmacist Medicine, Deputy Executive Medical Director, LMC rep2, Clinical Director Medicine Clinical Board, Associate Medical Director Primary Care, Assistant Director Finance, Clinical Director Mental Health Clinical Board.

Apologies: Clinical Board Pharmacist C&W, Clinical Director C&W Clinical Board, Clinical Board Pharmacist Mental Health. Executive Medical Director.

Welcome

2. Declarations of interest

Nil

3. Notes of last meeting (4/8/22)

Approved

Slenyto – correspondence received from AWMSG, to be discussed at October cMMG.

4. Matters arising

a) Safe use of Valproate – update paper

XX presented a paper updating the group on progress to date. cMMG satisfied with progress so far and thanked XX for presenting the paper.

5. Items for discussion/approval

a) cMMG updated ToR

Updated ToR presented after comparison against other organisations ToR, more accurate reflection of cMMG function – approved.

6 Financial position – medicines management

a) Finance position update month 4

Mth 4 Operational £0.516m mainly PCIC prescription growth (growth c2.5% - in line with national position). To note there are new arising pressures, Cat M and NCSO - HB position is similar to other HBs with benchmarking and comparison work.

The savings tracker has £3.182m this year but more recurrent savings required.

7. IPDs and pathways to note

a) IPD – Asciminib for CML

Hospital only following NICE TA. Low patient numbers – approved.

b) *IPD – Cariprazine for schizophrenia in adults*

Second line therapy for a specific population of patient. Applied for Hospital only status but IPD refers to GP prescribing. cMMG agreed Hospital Only is appropriate (plus more detail of steps for contraception assurance) – IPD to be amended and reviewed before approval.

c) *IPD- Fenfluramine for Dravets syndrome*

Hospital only, limited use expected. Approved for hospital only use.

8.

Formulary update

a) Lurfobec MDI SBAR

XX presented SBAR for more cost-effective equivalent of Fostair, discussion around the benefits of changing from MDI to MDI with larger green work changing away from MDI – in light of financial pressures this is a straight forward cost effective change whereas change to DPI significantly more labour intensive. Approved.

b) Fixkoh DPI SBAR

Presented as cost-effective version of Seretide – straight change of product using same device – approved.

c) LAT SBAR

XX presented paper detailing change in topical anaesthesia in the Children's Emergency Unit – approved.

d) Vitamin SBAR

XX presented paper detailing recommended vitamin regimen in CF with addition to formulary – approved.

e) *Medicines for ratification*

To be updated with approved IPDs.

9.

Other items to note

Colon Capsule Chart

Developed for use in gastroenterology

SBAR Plenvu

Item already on formulary and being used – change driven by shortage of moviprep – to make cMMG aware of change.

AWTTC Consultation - polypharmacy

Current consultation on updated polypharmacy guidelines – closes 12/9

Antimicrobial Improvement Goals data

C&V performing well currently – to continue current work.

10. Any other business

Date of next meeting **Thursday 6th October** 2022, 8.30 – 9.30, via TEAMS